Repository logo
 
Publication

A prime-boost immunization strategy with vaccinia virus expressing novel gp120 envelope glycoprotein from a CRF02_AG isolate elicits cross-clade tier 2 HIV-1 neutralizing antibodies

2020-06Contribution to journal Open access
Simple item page
datacite.subject.fosCiências Médicas
datacite.subject.sdg03:Saúde de Qualidade
dc.contributor.authorCalado, Rita
dc.contributor.authorDuarte, Joana
dc.contributor.authorBorrego, Pedro
dc.contributor.authorMarcelino, José Maria
dc.contributor.authorBártolo, Inês
dc.contributor.authorMartin, Francisco
dc.contributor.authorFigueiredo, Inês
dc.contributor.authorAlmeida, Silvia
dc.contributor.authorLuís, Graça
dc.contributor.authorVítor, Jorge
dc.contributor.authorSilva, Frederico Aires da
dc.contributor.authorDias, Inês
dc.contributor.authorCarrapiço, Belmira
dc.contributor.authorTaveira, Nuno
dc.date.accessioned2025-09-04T15:14:05Z
dc.date.available2025-09-04T15:14:05Z
dc.date.issued2020-06
dc.description.abstractDevelopment of new immunogens eliciting broadly neutralizing antibodies (bNAbs) is a main priority for the HIV-1 vaccine field. Envelope glycoproteins from non-B-non-C HIV-1clades have not been fully explored as components of a vaccine. We produced Vaccinia viruses expressing a truncated version of gp120 (gp120t) from HIV-1 clades CRF02_AG, H, J, B, and C and examined their immunogenicity in mice and rabbits. Mice primed with the recombinant Vaccinia viruses and boosted with the homologous gp120t or C2V3C3 polypeptides developed antibodies that bind potently to homologous and heterologous envelope glycoproteins. Notably, a subset of mice immunized with the CRF02_AG-based envelope immunogens developed a cross-reactive neutralizing response against tier 2 HIV-1 Env-pseudoviruses and primary isolates. Rabbits vaccinated with the CRF02_AG-based envelope immunogens also generated potent binding antibodies, and one animal elicited antibodies that neutralized almost all (13 of 16, 81.3%) tier 2 HIV-1 isolates tested. Overall, the results suggest that the novel CRF02_AG-based envelope immunogens and prime-boost immunization strategy elicit the type of immune responses required for a preventive HIV-1 vaccine.eng
dc.identifier.citationCalado R, Duarte J, Borrego P, Marcelino JM, Bártolo I, Martin F, Figueiredo I, Almeida S, Graça L, Vítor J, et al. A Prime-Boost Immunization Strategy with Vaccinia Virus Expressing Novel gp120 Envelope Glycoprotein from a CRF02_AG Isolate Elicits Cross-Clade Tier 2 HIV-1 Neutralizing Antibodies. Vaccines. 2020; 8(2):171. https://doi.org/10.3390/vaccines8020171
dc.identifier.doi10.3390/vaccines8020171
dc.identifier.issn2076-393X
dc.identifier.urihttp://hdl.handle.net/10400.26/58559
dc.language.isoeng
dc.peerreviewedyes
dc.publisherMDPI
dc.relation.hasversionhttps://doi.org/10.3390/vaccines8020171
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectHIV-1 vaccine
dc.subjectRecombinant Vaccinia virus
dc.subjectenvelope glycoproteins
dc.subjectnon-B-non-C clades
dc.subjectBALB/c mice
dc.titleA prime-boost immunization strategy with vaccinia virus expressing novel gp120 envelope glycoprotein from a CRF02_AG isolate elicits cross-clade tier 2 HIV-1 neutralizing antibodieseng
dc.typecontribution to journal
dspace.entity.typePublication
oaire.citation.issue2
oaire.citation.startPage171
oaire.citation.titleVaccines
oaire.citation.volume8
oaire.versionhttp://purl.org/coar/version/c_970fb48d4fbd8a85

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Artigo_NTaveira_2020_05.pdf
Size:
4.63 MB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.85 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

EM - Artigos Científicos